Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18249511 | 0.98 | TGM2 (0.53) | TGM2SMN1; SMN2GAAMAPTHDAC2 | |
| SCHEMBL15939027 | 0.87 | TGM2 (0.54) | TGM2SMN1; SMN2GAAMAPTHDAC2 | |
| SCHEMBL18256266 | 0.84 | TGM2 (0.59) | TGM2SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL21894170 | 0.83 | TGM2 (0.58) | TGM2SMN1; SMN2GAAMAPTHDAC2 | |
| SCHEMBL31162390 | 0.83 | TGM2 (0.58) | TGM2SMN1; SMN2GAAMAPTHDAC2 | |
| SCHEMBL23652898 | 0.82 | TGM2 (0.53) | TGM2SMN1; SMN2GAAMAPTHPGD | |
| SCHEMBL3870279 | 0.81 | GAA (0.67) | TGM2SMN1; SMN2GAAMAPTTP53 | |
| SCHEMBL15551319 | 0.80 | HDAC2 (0.51) | SMN1; SMN2GAAMAPTHDAC2HPGD | |
| SCHEMBL15938273 | 0.80 | MEN1 (0.43) | TGM2SMN1; SMN2MAPTHDAC2HPGD | |
| SCHEMBL17524715 | 0.80 | TGM2 (0.54) | TGM2SMN1; SMN2GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| EP-3179858-B1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | CELGENE CAR LLC (BM) | 2019-05-15 | — | — | EP | disclosed |
| US-10202364-B2 | Forms and compositions of an ERK inhibitor | CELGENE CAR LLC (BM) | 2019-02-12 | — | — | US | disclosed |
| US-20180362498-A1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-20 | — | — | US | disclosed |
| US-10005760-B2 | Forms and compositions of an ERK inhibitor | CELGENE CAR LLC (BM) | 2018-06-26 | — | — | US | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170226083-A1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-10 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| WO-2016025639-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025649-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A DOT1L INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025648-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A RAF INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025621-A1 | METHODS OF TREATMENT USING AN ERK INHIBITOR | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025651-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A TOR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2953457-A2 | ERK INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| WO-2014124230-A2 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202364-B2 | Forms and compositions of an ERK inhibitor | MAPK1, MAP3K20, MAPK3 | TGM2 3923/4885SMN1; SMN2 4109/4885GAA 3332/4885 |
| US-20180362498-A1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | MAPK1, MAP3K20, MAPK3 | TGM2 3923/4885SMN1; SMN2 4109/4885GAA 3332/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | TGM2 2577/4885SMN1; SMN2 3812/4885GAA 2716/4885 |
| US-20170226083-A1 | FORMS AND COMPOSITIONS OF AN ERK INHIBITOR | MAPK1, MAP3K20, MAPK3 | TGM2 3923/4885SMN1; SMN2 4109/4885GAA 3332/4885 |
| US-10005760-B2 | Forms and compositions of an ERK inhibitor | MAPK1, MAP3K20, MAPK3 | TGM2 3923/4885SMN1; SMN2 4109/4885GAA 3332/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | TGM2 3278/4885SMN1; SMN2 4304/4885GAA 3334/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | TGM2 3278/4885SMN1; SMN2 4304/4885GAA 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.